contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


realheart-is-granted-patent-approval-in-india-for-its-device-used-in-the-surgical-implantation-of-realheartr-tah

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Scandinavian Real Heart är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling inom observationer av hjärtats fysiologi. Utvecklingen av bolagets produkt, ett komplett artificiellt hjärta (TAH), sker i samarbete med hjärtkirurger, forskare och ingenjörer. Fokus ligger mot att utveckla patenterade lösningar som kan imitera det naturliga mänskliga hjärtats blodcirkulation. Lösningarna avses användas av patienter som diagnostiserats med hjärtsvikt.

Scandinavian Real Heart

Västerås, Sweden, November 20, 2024 – Scandinavian Real Heart AB (publ) announces today that the company has been granted an approval by Intellectual Property India for its patent application...

<div class="mfn-preamble"><p><strong>Västerås, Sweden, November 20, 2024 – Scandinavian Real Heart AB (publ) announces today that the company has been granted an approval by Intellectual Property India for its patent application (no. 202117045813) concerning a technical application related to the clinical use of Realheart® TAH.</strong></p></div><div class="mfn-body"><p>The approved patent pertains to a vascular coupling device, which is used to connect Realheart® TAH to the major vessels of the circulatory system. The duration of the patent (no. 552361) is 20 years, which will thus expire in April 2042.</p><p>“We are very happy that the patent authority in India has granted us a patent approval that complements and further strengthens our IP portfolio in India, which is a valuable as fast-growing market. While the U.S. remains our most prioritized market in the short term, we see great potential in the Indian market to realize the company’s long term growth potential,” says Ina Laura Perkins, CEO of Realheart.</p></div><div class="mfn-footer mfn-contacts mfn-ddde9c982a0b"><p><strong class="mfn-heading-1">For more information, please contact:</strong><br>Ina Laura Perkins, CEO<br>Phone: +46 (0) 70 406 49 21&nbsp;<br>E-mail: <a rel="noopener" href="mailto:inalaura.perkins@realheart.se">inalaura.perkins@realheart.se</a><br>Certified Adviser: Svensk Kapitalmarknadsgranskning AB, <a rel="noopener" href="http://www.skmg.se">www.skmg.se</a></p></div><div class="mfn-footer mfn-about mfn-0285b54ad9f5"><p><strong class="mfn-heading-1">About Us</strong><br>Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trial models ahead of a first clinical study in patients. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit <a rel="noopener" href="http://www.realheart.se">www.realheart.se</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/81b76b10-dd59-483c-9168-209eb5c91d55/realheart-is-granted-patent-approval-in-india-for-its-device-used-in-the-surgical-implantation-of-realheart-r-tah.pdf" class="mfn-generated mfn-primary">Realheart Is Granted Patent Approval in India for Its Device Used in the Surgical Implantation of Realheart® TAH</a></p></div>

Realheart Is Granted Patent Approval in India for Its Device Used in the Surgical Implantation of Realheart® TAH

Return on capital (ROE, ROI, ROIC, RONIC)

What does negative working capital mean and why is it a good thing?

Drug development investment: Value creation through M&As and licensing agreements

Income statement

Amazon continues to grow in Sweden

Beställ vårt nyhetsbrev — inget användarkonto krävs!